PAM - UEC HEPA and YPF among pre market gainers
Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim findings from trial for patients with chronic cough Aterian (NASDAQ:ATER) +21%. REGENXBIO (NASDAQ:RGNX) +19% AbbVie and REGENXBIO team up for eye disease therapy in $1.5 billion deal Hepion Pharmaceuticals (NASDAQ:HEPA) +18% additional data from Hepion Pharmaceuticals’ phase 2a ‘AMBITION’ rial further strengthens CRV431 clinical profile and paves way for initiation of Phase 2b ‘ASCEND-NASH’ clinical program Adaptimmune Therapeutics (NASDAQ:ADAP)+14% updates early-stage for solid tumor candidate Grupo Financiero Galicia (NASDAQ:GGAL) +15%. Pampa Energia (NYSE:PAM) +15%. Central Puerto (NYSE:CEPU) +13%. Grupo Supervielle (NYSE:SUPV) +13%. Banco Macro (NYSE:BMA) +12%. YPF Sociedad Anonima (NYSE:YPF) +10%. Telecom Argentina (NYSE:TEO) +10%. Transportadora de Gas del Sur (NYSE:TGS) +10%. Uranium Royalty (NASDAQ:UROY) +10%. Virpax Pharmaceuticals (NASDAQ:VRPX) +9%. Glory Star New Media (NASDAQ:GSMG) +8%. aTyr Pharma (NASDAQ:LIFE) +8% after success
For further details see:
UEC, HEPA and YPF among pre market gainers